Search
Press release
Press
April 28, 2021

Evonik enhances its production capabilities of nanoparticles for dentistry specialties at Geesthacht facility

  • New multipurpose reactor enables production flexibility to support changing customer requirements
  • Facility frees up laboratory resources for development of new applications
  • Enhanced silicone and nanotechnology capabilities strengthen Evonik’s focus on key growth markets

Geesthacht/Essen. Evonik’s multi-purpose silicone and nanotechnology manufacturing facility in Geesthacht, Germany has been further boosted with the completion of its new multi-purpose reactor. The new plant will help to meet increasing demand for its high value growth specialties products, including for example the acrylate resins filled with nanoparticles used in dentistry applications such as component fillings or artificial teeth.

Specifically developed to produce products like Nanocryl D which increases the service life of expensive dental prostheses by providing abrasion resistance, the unique set-up of the small-scale vessel enables quick changes in production to meet customer requirements. This flexibility also allows for further adaptations to quickly switch production to other attractive growth markets, like electronic applications.

“Previously, our team at Geesthacht could produce the specialist materials our customers needed in our laboratory, but production capacity was unable to keep pace as demand for these products has grown”, said Stefan Plass, Head of Evonik Interface & Performance. “Additionally, our customers are increasingly looking for more customized solutions, so to meet these growing requirements, we strengthened our nanoparticles capabilities with the investment in a new small-scale multipurpose reactor.”

The additional potential for product customization for customers enables Evonik’s Interface & Performance business line to further differentiate itself in the market. While at the same time, moving small volume specialties to the new plant, frees up laboratory resources and capacities for the development of other products outside the usual silicone and nanotechnology specialty chemical products.

Located in northern Germany, 30 kilometers outside Hamburg, this latest investment into the construction of the new small-scale reactor at Geesthacht follows Evonik’s previous investment in its silicone and nanotechnology at the site.

In addition to the new acrylate resins filled with nanoparticles for use in dentistry applications, other products produced in Geesthacht include, curing silicones and silane-modified-polymers (SMP’s) used as binders for adhesives and sealants in parquet adhesives, adhesives for wound care and other medical applications, and for example thermally conductive polymer filling compounds for e-mobility.

Company information

Evonik is one of the world leaders in specialty chemicals. The company is active in more than 100 countries around the world and generated sales of €12.2 billion and an operating profit (adjusted EBITDA) of €1.91 billion in 2020. Evonik goes far beyond chemistry to create innovative, profitable and sustainable solutions for customers. More than 33,000 employees work together for a common purpose: We want to improve life today and tomorrow.

About Specialty Additives

The Specialty Additives division combines the businesses of versatile additives and high-performance crosslinkers. They make end products more valuable, more durable, save more energy and simply better. As formulation experts in fast growing markets such as coatings, mobility, infrastructure and consumer goods, Specialty Additives combines a small amount with a big effect. With its 3,700 employees the division generated sales of €3.23 billion in 2020.

Disclaimer

In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.